The present invention relates to a method for the production of palladium(0) powder in which a palladium(0) starting powder is subjected to a thermal treatment in a furnace at a temperature of no more than 370° C. in a hydrogen gas atmosphere.

The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.

The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.

A system and method for removing acetic acid and other short chain fatty acids described as organic acid from a rich mono-ethylene glycol (“MEG”) solution does so by stripping the organic acid from the rich MEG solution by contacting the solution with a gas, the gas being nitrogen or a fuel gas such as methane; and stripping the organic acid from the gas by contacting the gas with a caustic solution such as a dilute sodium hydroxide solution. The stripping takes place in respective stripping columns. A portion of the gas exiting the gas/organic acid stripping column can be recycled to the MEG/organic acid stripping column to reduce total gas usage. A portion of the waste stream exiting the gas/organic acid stripping column can be recycled back to the gas/organic acid stripping column to reduce the amount of caustic solution used as well as the amount of waste.

A system and method for removing acetic acid and other short chain fatty acids described as organic acid from a rich mono-ethylene glycol (“MEG”) solution does so by stripping the organic acid from the rich MEG solution by contacting the solution with a gas, the gas being nitrogen or a fuel gas such as methane; and stripping the organic acid from the gas by contacting the gas with a caustic solution such as a dilute sodium hydroxide solution. The stripping takes place in respective stripping columns. A portion of the gas exiting the gas/organic acid stripping column can be recycled to the MEG/organic acid stripping column to reduce total gas usage. A portion of the waste stream exiting the gas/organic acid stripping column can be recycled back to the gas/organic acid stripping column to reduce the amount of caustic solution used as well as the amount of waste.

A quaternary ammonium salt of formula wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from an optionally substituted alkyl, alkenyl or aryl group having less than 8 carbon atoms and R.sup.5 is hydrogen or an optionally substituted hydrocarbyl group.

##STR00001##

A quaternary ammonium salt of formula wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from an optionally substituted alkyl, alkenyl or aryl group having less than 8 carbon atoms and R.sup.5 is hydrogen or an optionally substituted hydrocarbyl group.

##STR00001##

The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.

The present disclosure relates to crystalline forms of 4,5,6,7-tetrahydro-11-methoxy-2-[(4-methyl-1-piperazinyl)methyl]-1H-cyclopenta[a]pyrrolo[3,4-c]carbazole-1,3(2H)-dione, including salts forms and free base forms.

The present invention belongs to the pharmaceutical field, and provides the pharmaceutically acceptable salts of the compound (S)-7-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido[3,4-b]pyrazin-5-amine and the crystalline forms thereof, the solvates and the crystalline forms thereof, the pharmaceutical compositions comprising the same as well as the methods of preparing the same and the use thereof.